Actively Recruiting
Comparing Moxidectin Versus Ivermectin with Diethylcarbamazine and Albendazole for Treating Lymphatic Filariasis, Scabies, and Strongyloidiasis in Fiji
Led by Medicines Development for Global Health · Updated on 2026-10-07
5100
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether mass drug administration using moxidectin combined with diethylcarbamazine and albendazole MoxDA can effectively treat lymphatic filariasis, scabies, and strongyloidiasis in children and adults living in areas where these diseases are common. This phase 3 clinical trial compares MoxDA with ivermectin combined with diethylcarbamazine and albendazole IDA to determine which treatment better clears infection and whether either causes more medical problems. Participants will be randomly assigned to receive either three single doses of MoxDA or IDA, spaced 12 months apart. Those who cannot take moxidectin due to age or health reasons will receive modified treatments such as diethylcarbamazine, albendazole, and permethrin cream. After each treatment, participants will visit their village center once or twice within a week for safety checkups. Throughout the study, participants will be tested for infections caused by the parasites responsible for the diseases. Researchers will measure the proportion of participants clearing infection at 12 and 24 months, track adverse events up to 24 months after treatment, and evaluate changes in community disease prevalence. Safety monitoring and community acceptability assessments will also occur, with the total study duration lasting up to approximately two years after the first treatment.
CONDITIONS
Brief Title
Better Options for Lymphatic Filariasis Treatment
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here